NCT06827145

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

An Open-label, Single-center, Single-arm Phase IIa Study to Evaluate the Safety and Efficacy of Vebreltinib in Combination with Osimertinib in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR 21 L858R Mutation

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: National Cancer Center, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation

Conditions

• Non-Small-Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Vebreltinib	Vebreltinib 100mg oral BID
DRUG	Osimertinib	Osimertinib 80mg oral once daily.

Timeline

• Start date: 2024-10-14
• Primary completion: 2026-09-01
• Completion: 2028-09-01
• First posted: 2025-02-14
• Last updated: 2025-02-14

Locations

1 site across 1 country: China